Triple therapy immunosuppression in cadaveric renal transplantation.
One hundred and ninety-two patients received 200 consecutive cadaver renal transplants (158 first and 42 regrafts) and were treated with triple therapy immunosuppression consisting of low-dose cyclosporin, azathioprine and prednisolone. One-year patient and graft survival rates were 95% and 82%, respectively. Against this low rate of graft loss, the proportion of rejection-free patients in the first 3 months was strongly related to matching for HLA-DR (P less than 0.01), although HLA-DR matching was not associated with improved graft survival. More grafts were lost to nonimmunological causes than to rejection, and these losses fell into three main categories, namely, losses in elderly and diabetic patients and losses due to renal vascular thrombosis. Thus, triple therapy immunosuppression appears to offer effective immunosuppression, resulting in good graft and patient survival, especially in highly sensitised patients or patients receiving regrafts. There are relatively few serious adverse effects, although elderly and diabetic patients experienced significant morbidity and mortality after transplantation.
Richardson
A J
AJ
Nuffield Department of Surgery Transplant Unit, Churchill Hospital, Headington, Oxford, UK.
Higgins
R M
RM
Ratcliffe
P J
PJ
Ting
A
A
Murie
J
J
Morris
P J
PJ
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use*; D002102:Cadaver; D003524:Cyclosporins / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival / Q000187:drug effects*; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D011183:Postoperative Complications; D011239:Prednisolone / Q000627:therapeutic use*; D012086:Reoperation
D003524:Cyclosporins; D011239:Prednisolone; D001379:Azathioprine